Short answer · Medically reviewed summary · Last updated: 2026-04-07
Peutz-Jeghers syndrome was first clinically described in the early 20th century, notably by Jan Peutz in 1921 and Harold Jeghers in 1949, who linked characteristic mucocutaneous pigmentation to intestinal polyposis. While originally viewed as a rare clinical curiosity, the understanding of Peutz-Jeghers syndrome has evolved significantly, shifting from a focus on surgical management to a complex genetic framework centered on the STK11 gene. Who first described Peutz-Jeghers syndrome? The history of Peutz-Jeghers syndrome began with Jan Peutz, a Dutch physician who reported a family with polyposis and dark skin spots in 1921.
Peutz-Jeghers syndrome was first clinically described in the early 20th century, notably by Jan Peutz in 1921 and Harold Jeghers in 1949, who linked characteristic mucocutaneous pigmentation to intestinal polyposis. While originally viewed as a rare clinical curiosity, the understanding of Peutz-Jeghers syndrome has evolved significantly, shifting from a focus on surgical management to a complex genetic framework centered on the STK11 gene.
The history of Peutz-Jeghers syndrome began with Jan Peutz, a Dutch physician who reported a family with polyposis and dark skin spots in 1921. However, the condition did not gain widespread international recognition until 1949, when Harold Jeghers, an American physician, published a landmark paper in the New England Journal of Medicine. Jeghers meticulously detailed the association between the pigmented spots on the lips and oral mucosa and the presence of hamartomatous polyps in the gastrointestinal tract, effectively defining the clinical entity now known as Peutz-Jeghers syndrome.
For decades, Peutz-Jeghers syndrome was primarily managed as a surgical challenge, with doctors focusing on removing polyps to prevent bowel obstruction. It was not until the late 20th century that the focus shifted to the significantly increased risk of various cancers. In 1998, researchers identified mutations in the STK11 (also known as LKB1) gene on chromosome 19p13.3 as the primary cause of the condition. This discovery transformed Peutz-Jeghers syndrome from a purely symptomatic diagnosis into a condition that could be definitively identified through genetic testing, allowing for preemptive cancer surveillance programs.
Historically, patients with Peutz-Jeghers syndrome often underwent multiple emergency laparotomies, which caused significant physical and psychological trauma. The evolution of care has been marked by several key shifts:
Early medical literature often conflated Peutz-Jeghers syndrome with other polyposis conditions, such as Familial Adenomatous Polyposis (FAP). Before the identification of the STK11 gene, diagnosis relied entirely on the observation of physical symptoms, which often led to missed cases in individuals who lacked prominent pigmentation. Genetic testing has since clarified that Peutz-Jeghers syndrome follows an autosomal dominant inheritance pattern, meaning a parent with the condition has a 50% chance of passing it to their child, fundamentally changing how families approach genetic counseling and family planning.
Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.